Erika (Cawthron) Gill

Erika Gill is a purpose-driven executive with over 20 years of experience leading diverse teams across commercial functions in the biopharmaceutical industry. She currently serves as U.S. General Manager for Huntington’s Disease at Novartis, where she brings her expertise in strategic planning, product development, and launch excellence to advance therapies that make a meaningful difference for patients.

Previously, Erika was Vice President and Head of Neuroscience Global Product and Launch Strategy at Takeda, where she successfully led cross-functional teams in the development of global launch strategies for multiple Phase 3 assets and a $4B in-line commercial asset. Over the course of her career, she has launched five assets in the U.S. and globally, established go-to-market strategies, and managed complex alliances for co-promotion agreements.

Erika has also overseen critical initiatives in field leadership, commercial operations, and patient services—designing nursing, reimbursement, and case management programs, and managing multi-million dollar budgets to enhance customer experience and operational efficiency.
She holds a BS in Health Management and Policy from the University of New Hampshire and an MBA from Boston University.

Connect with Erika Gill on LinkedIn.